# A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis

> **NCT01917019** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 101 (actual)

## Conditions studied

- Multiple Sclerosis, Remittent Progressive
- Multiple Sclerosis, Primary Progressive
- Relapsing-Remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis
- Multiple Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** BIIB041 (fampridine)

## Key facts

- **NCT ID:** NCT01917019
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-10
- **Final completion:** 2017-03
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01917019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01917019, "A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01917019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*